–News Direct–

FTN Network, a company built for delivering affordable, customizable, and highly detailed NFL advanced charted data for betting, season-long fantasy, and daily fantasy, ushered the 2024 football season today with the release of its 2024 NFL Draft Team Grades and 2024 Rookie Fantasy Scouting Guide 2.0. The guide, which is authored by FTN President and Sirius XM Radio Host Jeff Ratcliffe, features rookie rankings, projections, veteran comps, dynasty value, trade value charts, draft boards, and more.

FTNs 2024 football season started on a high note with a successful weekend of NFL Draft coverage after providing NFL fans with some the most accurate set of mock drafts in the industry. In a field of 137 contestants, three FTN analysts finished in the top 15 of the FantasyPros mock draft accuracy contest: Tyler Loechner (4th place), Ratcliffe (13th), and Chris Meaney (14th). No other media company had two or more analysts finish inside the top 20 and Ratcliffe has now finished 13th or better in back-to-back years.

FTNs coverage included a live blog with instant reactions and fantasy projections from Ratcliffe for every fantasy-relevant rookie selected during the first three rounds of the draft. In addition to Ratcliffes projections and analysis, the coverage included insight from FTNs Chief Analytics Officer and DVOA inventor Aaron Schatz, Mike Randle, Meaney, fantasy analyst Adam Pfeifer, and rookie expert Jeremy Popielarz. FTN also produced immediate, instant-reaction video breakdowns during the first night of the draft.

We provided fans with the most accurate information before the draft, live fantasy analysis during the draft across multiple mediums and the most comprehensive rookie fantasy scouting guide in the market, said FTN Network CEO Perry Gershon. Our extensive coverage of the NFL draft and our ongoing analysis of the incoming rookie class continues to prove that FTN is the one-stop-shop for NFL fans, fantasy players and bettors.

Along with pre, post and in-draft content, Randle gave all 32 NFL teams a 2024 Draft grade on the A-F scale. The Pittsburgh Steelers, Miami Dolphins and Los Angeles Chargers topped Randles charts with A+, A and A grades, respectively. The Carolina Panthers, Las Vegas Raiders and Dallas Cowboys rounded out the bottom of the 32 teams, receiving C grades. Additionally, Randle provided fantasy grades for every team that saw the Chargers score the highest (A+) and the Atlanta Falcons and Cowboys score the lowest (F).

While Ratcliffes 2024 Rookie Fantasy Scouting Guide had been released prior to the draft, version 2.0 is now live and includes post-draft information. It can be found here. The guide includes 150 player-by-player breakdowns, draft boards, player comps, rankings for regular and superflex leagues, a dynasty rookie pick trade value chart and more and will be continuously updated before the start of the 2024 NFL season.

About FTN Network

FTN Network is a sports data B2B and fantasy sports and betting media B2C company. Founded in 2020, FTN gives the fantasy and sports betting community an edge through their own unique ecosystem – providing customizable tools that turn raw data into true insights while also offering expert analysis and content to help users make the best decision possible.

Contact Details

Hot Paper Lantern

Sterling A. Randle

+1 801-319-6153

[email protected]

View source version on newsdirect.com: https://newsdirect.com/news/ftn-network-releases-2024-nfl-draft-team-grades-and-rookie-fantasy-scouting-guide-following-2024-nfl-draft-828828244

FTN Network

COMTEX_451716095/2655/2024-05-01T09:02:25

–News Direct–

The second annual and first standalone Air|Water Porsche enthusiast show, produced by the Luftgekhlt events team, celebrated a tremendous success this weekend, with artistically curated cars attracting more than 11000 enthusiasts, who immersed themselves in the celebration of 75 years of everything Porsche.

The team welcomed more than 1000 registered display cars spread throughout the 130 acre site at the Orange County Fair & Event Center. There was no shortage of discoverable experiences and aching feet. From the galleries created in the six main exhibition halls, to the off-road and rallye machines in the Action Sports Arena, the Broad Arrow Live Auction in The Hangar, and a sold-out exhibit hall featuring companies catering to the Porsche enthusiast, there was something for everybody at Air|Water. Also featured were 33 white Porsches in the Pacific Amphitheatre, custom restored builders in Park Plaza, and a barn full of vintage finds. The display cars even stretched across several expansive lots as Air|Water provided an unforgettable day for Porsche fans.

In addition to spectacles such as a Porsche-powered Formula 1 car, Le Mans winners, and Pikes Peak entrants, visitors were able to meet VIPs including the show organizers and decorated racers Patrick Long and Jeff Zwart, plus Porsche Factory racers Jrg Bergmeister and Alwin Springer.

While there were long lines at times for the clothing capsule and event merchandise, visitors and fans are now able to purchase any of the Air|Water items from the comfort of their sofa via luftgekuhlt.com/collections

The entire Air|Water team would like to thank everybody who attended the show, the owners who displayed their cars, the brands that participated, the collectors who provided the extremely significant featured cars, and the event partners who contributed to the overall experience. It takes a village and were delighted to be part of yours!

LUFTGEKHLT

The next project for the team is the annual Luftgekhlt show. Dedicated purely to air-cooled Porsches and held at a unique location each year, the show has become a staple of the Porsche lifestyle calendar. Returning to Southern California in October this year, more details will be available via the Luftgekhlt social media channels and newsletter, which can be joined here: luftgekuhlt.com

EDITORS NOTE

Images from Air|Water 2024 are available here: dropbox.com/sh/zz14duvaes4t6br/AACT_4M-bs9v8lUbSqGSh6vja?dl=0

ABOUT AIR|WATER

From the creators of Luftgekhlt comes the largest single-brand automotive experience to hit Southern California. Embarking on a fresh format that traces Porsche's journey from its inaugural moments to the contemporary masterpieces and most cutting-edge examples of today. For more information, visit air-water.com

ABOUT LUFTGEKHLT

In the Porsche vernacular, Luftgekuhlt represents all the air-cooled cars in the manufacturers history, from the Pre-A 356 through the 993 model line, which ended in 1998. A true Porsche happening, Luftgekuhlt is an experiential car culture event centered around a tightly curated list of historically significant or interesting cars, both street and race. There is no set formula for our events, but we're excited by cool venues, fun people, and creative expression, so you can bet those elements will always be included. The team strives to develop wild ideas that celebrate the passion we have for all things air-cooled, including exciting collaborations with likeminded people and brands. For more information, visit luftgekuhlt.com

Contact Details

Media Contact

[email protected]

Company Website

https://air-water.com/

View source version on newsdirect.com: https://newsdirect.com/news/air-water-wraps-up-the-largest-porsche-gathering-to-hit-southern-california-767521294

Luftgekuhlt

COMTEX_451715245/2655/2024-05-01T08:54:24

–News Direct–

By Jeremy Golden, Benzinga

Artificial intelligence (AI) is on the cusp of transforming nearly every single industry. When it comes to healthcare, several trends have emerged.

As doctors and scientists continue to innovate, the market for AI in healthcare is expanding. The AI healthcare market appears poised for growth, with a market size of $22 billion in 2023 a number thats expected to accelerate at a CAGR of 36.4% from 2024-2030. The market for AI in healthcare is expected to reach $187.95 billion by 2030, demonstrating the transformative shift its brought to the healthcare industry.

AI-focused healthcare companies are driving this progress.

Here is how three healthcare companies are harnessing AIs capabilities, using technology to drive innovation, target treatments and increase access to healthcare.

Driving Innovation

The rapidly growing field of AI in healthcare is already coming to life at places like the Mayo Clinic, where several AI-powered medical and surgical improvements have validated new approaches to clinical care in cardiovascular medicine, neurology, oncology, radiology and other fields of medicine.

AI is replacing repetitive, manual processes such as patient data analysis that slow down healthcare professionals. Moving forward, this new technology will drive innovation, executives at Moderna (NASDAQ: MRNA) said after inking a partnership with OpenAI, the company behind ChatGPT, in April.

The move gave about 3,000 Moderna employees access to ChatGPT Enterprise, built on OpenAIs most advanced language model, GPT-4, the Wall Street Journal reports. Moderna anticipates the integration of AI could lead to the introduction of 15 new products by 2029, the Cambridge, Mass., company said.

Moderna CEO Stphane Bancel envisions employees using ChatGPT at least 20 times a day to reinvent all of Moderna's business processes, leading to greater overall efficiency. Heres one example.

When developing medicines, researchers study the biological and genetic variations that cause diseases to develop. Utilizing AI to dissect medical data sets like lab results can help scientists fill in the missing pieces. AI can assist them in figuring out the root cause of the disease, helping get much-needed treatments to patients faster.

AI can lift success rates to up to 50% while reducing a drugs time-to-market, a recent Moderna study by Harvard Universitys Digital Data Design Institute found.

AI is already transforming Moderna and enhancing its value-creation process. The companys position in AI-powered innovation is leading to more efficiency and scalability across the value chain due in large part to an AI-centric culture.

As of October 2023, nearly 65% of Moderna employees were active AI users. They have used the tool in multiple specific functions, from customized support to meaningful improvements in workflow efficiency and efficacy.

Moderna has plans to integrate AI into all aspects of the drug development life cycle. To that end, the company has launched the Moderna AI Academy to accelerate training on AI throughout the organization.

Targeted Treatments

In addition to advancing drug discovery, artificial intelligence is also helping treatments reach patients faster.

The past decade has seen an explosion in the amount of health data available to doctors. Organizing and analyzing this much data in a timely manner, however, can be a complex and time-consuming task for the human mind, no matter how capable or intelligent the person. Thats where AI comes in.

AI is enabling researchers to develop more targeted medicines, driving progress in the field of precision medicine. This trend was part of a presentation delivered by executives at Johnson & Johnson (NYSE: JNJ), who hosted a panel discussion about AIs role in transforming healthcare at this years South by Southwest conference. They touched on many topics, from AI applications in drug discovery to its ability to assist doctors during clinical trials.

When it comes to running clinical trials, one of the biggest challenges is quickly and efficiently recruiting and enrolling patients who meet the selection criteria.

By applying AI technology to the early stages of a clinical trial, Johnson & Johnson researchers can use large anonymized datasets to identify and locate clinical research sites with patients who could potentially benefit from the Johnson & Johnson medicines that are being studied.

From there, the clinical trial operations team can work to determine the likelihood of enrolling the newly identified sites into their trials.

Historically, many clinical trials have largely taken place at major academic medical centers, but we know that not all patients have access to these centers, said Nicole Turner, Senior Director of Global Development, Data Science & Digital Health and R&D at Janssen Pharmaceuticals. Our goal is to leverage the power of AI to bring trials to more patients, rather than waiting for patients to come to us.

According to The Wall Street Journal, Johnson & Johnson continues to make investments to the tune of hundreds of millions of dollars in AI and data science.

The company has hired about 6,000 data science and digital experts and opened a new research facility near San Francisco, and company executives say AI will power the companys drug discovery work and strengthen its pharmaceuticals business in the future.

Increasing Access

Across the country, there is a need for more accessible and systemic healthcare solutions. One company is responding by using AI to combat cardiovascular diseases globally while committing to health equity and access.

AI algorithms can effectively handle and analyze extensive medical data, including DNA biomarkers such as epigenetic and genetic information. As such, the shift to digital health and AI-driven diagnostics could also have widespread impacts on the cardiovascular detection, care and management industry, helping increase access to healthcare in a timely manner across the board especially helping underserved communities in the process.

Cardio Diagnostics (NASDAQ: CDIO), an artificial intelligence-powered precision cardiovascular medicine company that makes cardiovascular disease prevention and detection more precise, was formed to improve patient outcomes by developing and commercializing clinical tests that leverage AI-driven technology to combat cardiovascular disease.

The company is behind PrecisionCHDTM, the first integrated genetic-epigenetic test for the detection of coronary heart disease (CHD), the most common type of heart disease and the cause of most heart attacks. With the introduction of PrecisionCHD, clinicians are armed with a powerful, scalable and non-invasive alternative that comes in the form of a blood-based test that uses AI, along with personalized genetic and epigenetic information, to sensitively detect the presence of CHD and use the information for more personalized patient management.

Cardio Diagnostics has also developed Epi+Gen CHDTM, a powerful test that predicts the three-year risk for a CHD event, mainly a heart attack. Powered by AI-driven integrated genetics-epigenetics, the tool enables more effective decision-making and earlier interventions.

Traditional diagnostic methods for CHD, often inaccessible due to the need for specialized infrastructure, can be invasive and sometimes require exposure to ionizing radiation. Additionally, some of the tests are not sensitive to all forms of CHD and can be very costly, resulting in millions of Americans left without adequate and potentially lifesaving cardiac care. Thanks to AI, PrecisionCHD has armed clinicians with a powerful, scalable and non-invasive alternative that comes in the form of a blood-based test.

For rural communities where access to specialized medical facilities is limited, the implications of this advancement are particularly relevant. With only a simple blood draw needed to complete a test, PrecisionCHD offers patients in underserved areas access to state-of-the-art cardiac assessments.

PrecisionCHD can be administered in primary care or telemedicine settings, significantly reducing the need for patients to travel to distant specialized clinics. This level of availability, marking a step forward toward mitigating healthcare disparities, would not be possible without AI.

Featured photo by CDC on Unsplash.

Cardio Diagnostics is an artificial intelligence-powered precision cardiovascular medicine company that makes cardiovascular disease prevention, detection, and management more accessible, personalized, and precise. The Company was formed to further develop and commercialize clinical tests by leveraging a proprietary Artificial Intelligence (AI)-driven Integrated Genetic-Epigenetic Engine (Core Technology) for cardiovascular disease to become one of the leading medical technology companies for improving prevention, detection, and treatment of cardiovascular disease. For more information, please visit www.cardiodiagnosticsinc.com.

Certain statements and information included in this press release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Act of 1995. When used in this press release, the words or phrases will, "will likely result," "expected to," "will continue," "anticipated," "estimate," "projected," "intend," goal, or similar expressions are intended to identify "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks, known and unknown, and uncertainties, many of which are beyond the control of the Company. Such uncertainties and risks include but are not limited to, our ability to successfully execute our growth strategy, changes in laws or regulations, economic conditions, dependence on management, dilution to stockholders, lack of capital, the effects of rapid growth upon the Company and the ability of management to effectively respond to the growth and demand for products and services of the Company, newly developing technologies, the Companys ability to compete, regulatory matters, protection of technology, the effects of competition and the ability of the Company to obtain future financing. An extensive list of factors that can affect future results are discussed in the Current Report on Form 10-K for the period ended December 31, 2022 and Form 10-Q for the period ended March 31, 2023, under the heading Risk Factors in Part I, Item IA thereof, and other documents filed from time to time with the Securities and Exchange Commission. Such factors could materially adversely affect the Company's financial performance and could cause the Company's actual results for future periods to differ materially from any opinions or statements expressed within this press release.

This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice.

Contact Details

Gene Mannheimer – Investor Relations

+1 855-226-9991

[email protected]

Company Website

https://cardiodiagnosticsinc.com/

View source version on newsdirect.com: https://newsdirect.com/news/3-trends-in-healthcare-guided-by-ai-and-the-companies-behind-the-innovation-489286769

Cardio Diagnostics Holdings, Inc

COMTEX_451714604/2655/2024-05-01T08:30:21